Clinical trials: Non-Valvular Atrial Fibrillation
Atrial Fibrillation
Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are…
- Trial name
- PINNACLE FLX (NCT02702271)
- Testing
- WATCHMAN FLX
- Where
- 29 sites in United States
- Volunteers
- 458 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
- Trial name
- DABI-F (NCT02687867)
- Testing
- Dabigatran (Pradaxa), Vitamin K antagonist
- Where
- United States
- Volunteers
- 56,039 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (AF)
Vortosiran in Atrial Fibrillation
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF.
- Trial name
- NCT07870889
- Testing
- Vortosiran, Apixaban
- Where
- 15 sites in Denmark, Norway and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Non Valvular Atrial Fibrillation
Applause Study I - Append System Early Feasibility Study
This early feasibility study is intended to evaluate the safety and feasibility of the Append System for eliminating the left atrial appendage (LAA) through a transcatheter procedure that invaginates and ligates the LAA tissue.
- Trial name
- Applause (NCT07278869)
- Testing
- Left Atrial Appendage Elimination: Append System
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Append Medical Ltd.
Non-valvular Atrial Fibrillation
Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs (Novel Oral Anticoagulants) in routine clinical practice in England
- Trial name
- NCT03508258
- Testing
- Non-interventional
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Nonvalvular Atrial Fibrillation
Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S Primary objective: To determine…
- Trial name
- NCT02674594
- Volunteers
- 30,000 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
1600 AF patients receiving Pradaxa or VKA for stroke prevention will be followed up for 12 months in quarterly visits. Prescriptions, adverse events and (if applicable) reasons for definitive treatment discontinuation will be…
- Trial name
- NCT02240667
- Testing
- Dabigatran etexilate, Vitamin K antagonists
- Where
- Germany
- Volunteers
- 1,506 people
- Sponsor
- Boehringer Ingelheim
Non-Valvular Atrial Fibrillation
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Atrial fibrillation is a heart condition that causes an abnormal and fast heart rate. For people with non-valvular atrial fibrillation (NVAF), this is caused by problems such as high blood pressure and diabetes.
- Trial name
- BELANCE (NCT04722679)
- Testing
- Non-VKA Oral Anticoagulants (NOAC)
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Bayer
Non-Valvular Atrial Fibrillation
Amplatzer Amulet China Post Market Study (PMS)
The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device.
- Trial name
- NCT06189365
- Testing
- Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
- Trial name
- NCT02754154
- Testing
- Warfarin, Apixaban, Dabigatran
- Volunteers
- 321,182 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) to gain insight into the safety…
- Trial name
- NCT03247569
- Testing
- Edoxaban
- Where
- 6 sites in Thailand
- Volunteers
- 300 people
- Sponsor
- Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation
Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)
Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
- Trial name
- NCT02654470
- Testing
- Watchman FLX
- Where
- 17 sites in Denmark, France and 7 more
- Volunteers
- 300 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.
- Trial name
- NCT02043808
- Where
- United States
- Volunteers
- 25,586 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly…
- Trial name
- NCT03026556
- Testing
- Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
- Where
- United States
- Volunteers
- 42,534 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.
- Trial name
- PIXI-F (NCT02687854)
- Testing
- Apixaban, Vitamin K antagonist
- Where
- United States
- Volunteers
- 18,591 people
- Sponsor
- Bayer
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
The objective of this study is to investigate safety and effectiveness of apixaban compared to warfarin in very elderly patients with Non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT05438888
- Testing
- Warfarin, Apixaban
- Where
- Japan
- Volunteers
- 77,814 people
- Sponsor
- Pfizer
Atrial Fibrillation
Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based…
- Trial name
- ELIMINATE-AF (NCT02942576)
- Testing
- Edoxaban, VKA-Based Regimen
- Where
- 75 sites in Belgium, Canada and 9 more
- Volunteers
- 632 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer